Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Journal of Virology
Staffan GöranderJan-Åke Liljeqvist

Abstract

The envelope glycoproteins of herpes simplex virus 1 (HSV-1) and HSV-2, with the exception of glycoprotein G, elicit cross-reactive B- and T-cell responses. Human vaccine trials, using the cross-reactive glycoproteins B and D, have shown no protection against genital HSV-2 infection or disease. In this study, the mature form of glycoprotein G (mgG-2) of HSV-2 was used for immunization of mice, either alone or in combination with adjuvant CpG, followed by an intravaginal challenge with a lethal dose of a fully virulent HSV-2 strain. Mice immunized with mgG-2 plus CpG showed low disease scores and a significantly higher survival rate (73%) than mice immunized with mgG-2 alone (20%) or controls (0%). Accordingly, limited numbers of infectious HSV-2 particles were detected in the spinal cord of mice immunized with mgG-2 plus CpG. The observed protection was associated with a gamma interferon (IFN-γ) response by splenic CD4(+) T cells upon antigen restimulation in vitro and in vaginal washes 1 day postinfection. The majority of sera collected from mice immunized with mgG-2 plus CpG showed macrophage-mediated antibody-dependent cellular cytotoxicity and antibody-dependent complement-mediated cytolysis, while no neutralization activit...Continue Reading

References

Jan 1, 1991·Annual Review of Immunology·J V Ravetch, J P Kinet
Jun 1, 1985·Journal of Virology·N Balachandran, L M Hutt-Fletcher
Dec 1, 1983·The Journal of General Virology·S OlofssonE Lycke
Aug 21, 1997·The New England Journal of Medicine·Z A BrownL Corey
Oct 27, 1997·The New England Journal of Medicine·D T FlemingM E St Louis
May 4, 2000·Virology·K L DudleyG N Milligan
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·W S GallichanK L Rosenthal
Sep 28, 2002·The Journal of Infectious Diseases·Jennifer S Smith, N Jamie Robinson
Oct 29, 2002·Cytokine & Growth Factor Reviews·David A Chesler, Carol Shoshkes Reiss
Nov 22, 2002·The New England Journal of Medicine·Lawrence R StanberryUNKNOWN GlaxoSmithKline Herpes Vaccine Efficacy Study Group
Jan 15, 2003·Clinical Microbiology Reviews·David M Koelle, Lawrence Corey
Apr 25, 2003·International Reviews of Immunology·Margaret B Parr, Earl L Parr
Oct 25, 2008·Bulletin of the World Health Organization·Katharine J LookerGeorge P Schmid

❮ Previous
Next ❯

Citations

Dec 4, 2012·Microbial Pathogenesis·Dorothee DulucSangkon Oh
Feb 28, 2013·Human Vaccines & Immunotherapeutics·Jeffrey L Coleman, Deepak Shukla
Feb 24, 2015·Archives of Virology·Karin ÖnnheimJan-Åke Liljeqvist
Dec 9, 2015·Antimicrobial Agents and Chemotherapy·Joanna S SaidTomas Bergström
Dec 4, 2019·AIDS Research and Human Retroviruses·Minkyo SongCharles S Rabkin
Jun 18, 2020·Vaccines·Anthony C IkeSophia O Muo
May 23, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yan YanQinxue Hu
Jun 25, 2015·Microbiology Spectrum·Donald N Forthal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.